A patient is taking warfarin 5 mg five days per week and now has a prothrombin time of 21.6 seconds, an INR of 1.97, and an activated partial thromboplastin time of 31.9 seconds; how should the warfarin dose be adjusted?

Warfarin Dose Adjustment for INR 1.97

Increase the warfarin dose by approximately 10-20% (add 0.5-1 mg per day to the weekly regimen) to bring the INR into the therapeutic range of 2.0-3.0. 11

Current Clinical Situation

Your patient's INR of 1.97 is just below the therapeutic range (target 2.0-3.0 for most indications). The PT of 21.6 seconds and APTT of 31.9 seconds are consistent with subtherapeutic anticoagulation. This patient requires dose escalation to achieve adequate thromboembolic protection.

Dose Adjustment Strategy

Immediate Action

• Do not hold any doses - the INR is not elevated 11
• Increase the total weekly dose by adding 2.5-5 mg per week (distributed across dosing days)
• For a patient currently taking 5 mg five days per week (25 mg/week total):
  • Option 1: Increase to 5 mg six days per week (30 mg/week)
  • Option 2: Increase to 5 mg five days + 7.5 mg one day per week (32.5 mg/week)

Rationale for Dose Increase

The American Heart Association/American College of Cardiology guidelines specify that when the INR is above therapeutic range but <5, dose reduction is appropriate 11. Conversely, when the INR is below therapeutic range (as in this case at 1.97), dose escalation is required to prevent thromboembolic events, which carry significant morbidity and mortality risk.

Monitoring Protocol

• Recheck INR in 3-5 days after dose adjustment 22
• Once stable in therapeutic range (2.0-3.0), extend monitoring intervals to 1-4 weeks 2
• The FDA label emphasizes that PT/INR should be determined daily initially until results stabilize, then at intervals based on patient reliability 2

Critical Considerations

Target INR Range

• Standard therapeutic range: 2.0-3.0 for most indications (venous thromboembolism, atrial fibrillation) 12
• Higher intensity (INR 3.0-4.5) only for specific high-risk conditions like mechanical prosthetic valves 1
• Recent evidence suggests INR 1.5-2.5 may reduce bleeding risk, but this is not standard practice and should only be considered in patients with high bleeding risk 3

Common Pitfalls to Avoid

1. Do not make excessive dose changes - small adjustments (10-20%) prevent overshooting the therapeutic range 1
2. Do not wait too long to recheck - subtherapeutic anticoagulation increases thrombotic risk significantly
3. Assess medication adherence - confirm the patient is actually taking warfarin 5 days per week as prescribed
4. Review interacting medications - new drugs (especially antibiotics, antifungals, NSAIDs) can dramatically affect warfarin metabolism 24

Factors That May Require Larger Dose Increases

• Dietary vitamin K intake - increased green leafy vegetable consumption
• Drug interactions - enzyme inducers (rifampin, carbamazepine, phenytoin)
• Genetic factors - CYP2C9 and VKORC1 polymorphisms affect warfarin sensitivity 2

Quality of Care Enhancement

The guidelines emphasize that time in therapeutic range significantly impacts outcomes - patients managed by anticoagulation clinics achieve 56-93% time in range versus only 33-64% in usual care 2. Consider:

• More frequent monitoring during dose titration
• Patient education on dietary consistency
• Medication reconciliation at each visit

The priority is preventing thromboembolic events (stroke, PE, DVT) which have devastating morbidity and mortality consequences, while the current INR of 1.97 provides inadequate protection. 12